Clinical trials: Select Advanced Malignancies
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Non Small Cell Lung Cancer
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
- Trial name
- PROCLAIM (NCT00686959)
- Testing
- Pemetrexed, Cisplatin, Etoposide
- Where
- 133 sites in United States, Argentina and 17 more
- Volunteers
- 598 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic Breast Cancer
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast…
- Trial name
- DB-06 (NCT04494425)
- Testing
- Trastuzumab deruxtecan, Capecitabine, Paclitaxel
- Where
- 293 sites in United States, Argentina and 26 more
- Volunteers
- 866 people
- Sponsor
- AstraZeneca
Breast Neoplasms
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal…
- Trial name
- NCT06312176
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel
- Where
- 259 sites in United States, Argentina and 38 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to demonstrate that SYD985 [(vic-)trastuzumab duocarmazine] is superior to physician's choice in prolonging progression free survival.
- Trial name
- TULIP (NCT03262935)
- Testing
- (vic-)trastuzumab duocarmazine, Physician's choice
- Where
- 90 sites in United States, Belgium and 9 more
- Volunteers
- 437 people
- Sponsor
- Byondis B.V.
Advanced Cancer
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
This study will determine how nanatinostat is absorbed, modified, and removed from the body (Part A), the amount of nanatinostat that becomes available to the body (Part B), and will evaluate the safety and tolerability of…
- Trial name
- NCT06302140
- Testing
- [14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Viracta Therapeutics, Inc.
Colorectal Cancer, ADCC
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
Patients' selection thorough the identification of predictive factors still represent a challenge in metastatic colorectal cancer (mCRC).
- Trial name
- CIFRA (NCT03874026)
- Testing
- Folfiri/Cetuximab
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute, Naples
Non Small Cell Lung Cancer
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose…
- Trial name
- NCT04866017
- Testing
- Tislelizumab, Durvalumab, Ociperlimab
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- BeiGene
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal…
- Trial name
- NCT07518147
- Testing
- BL-M05D1, Paclitaxel, Docetaxel
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Solid Tumors
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
- Trial name
- NCT07158918
- Testing
- ABL103, KEYTRUDA® (pembrolizumab), Taxane
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 65 people
- Sponsor
- ABL Bio, Inc.
Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Trial name
- NCT07462650
- Testing
- EB-DUO-CAR-NK-CEA/GCC (IV)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Advanced and Selected Solid Tumors, AML
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally administered combination of BYL719 and MEK162.
- Conditions
- Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
- Trial name
- NCT01449058
- Testing
- BYL719, MEK162
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Array BioPharma
Advanced Solid Tumors
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab…
- Trial name
- NCT02671435
- Testing
- Monalizumab, Durvalumab, Cetuximab
- Where
- 49 sites in United States, Australia and 9 more
- Volunteers
- 383 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumors
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
The primary objectives of this trial are to: Characterize the safety and tolerability of TEV-56278 Determine the Recommended Phase 2 Dose (RP2D) Evaluate antitumor activity of TEV-56278 (Part 2 only) Determine the safety and…
- Trial name
- NCT06480552
- Testing
- TEV-56278, Pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or…
- Trial name
- NCT07621601
- Testing
- HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel
- Volunteers
- 494 people
- Sponsor
- Hansoh BioMedical R&D Company
Non Small Cell Lung Cancer
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
This is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients.
- Trial name
- TELMA (NCT03836066)
- Testing
- Atezolizumab-Bevacizumab
- Where
- 25 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Fundación GECP
Biliary Tract Cancer
Molecular Profiling of Advanced Biliary Tract Cancers
Biliary tract cancer (BTC) accounts for <1% of all cancers, but remains a highly fatal malignancy. Surgical resection is the only hope for cure, but most patients present with advanced disease when curative-intent surgery is not…
- Trial name
- COMPASS-B-MUHC (NCT04318834)
- Testing
- Tumour and germline molecular profiling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Carcinoma, Pancreatic Ductal
Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain…
- Trial name
- COMPASS (NCT02750657)
- Testing
- Molecular Profiling
- Where
- 4 sites in Canada
- Volunteers
- 332 people
- Sponsor
- University Health Network, Toronto
Solid Tumor, Adult
Study of DF1001 in Patients With Advanced Solid Tumors
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT04143711
- Testing
- DF1001, Nivolumab, Nab paclitaxel
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Dragonfly Therapeutics
Advanced Solid Tumors
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors
- Trial name
- NCT02318394
- Testing
- MEDI0562
- Where
- 12 sites in United States, South Korea
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC